Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : UTHR-a Promising Biotech in the works here? -- Ignore unavailable to you. Want to Upgrade?

To: red_dog who wrote (36)	8/31/1999 9:14:00 AM
From: kendall harmon	Read Replies (1) \| Respond to of 66

UTHR--Bt alex brown excerpts This morning, Stuart Rich, M.D., presented positive results of a Phase IIstudy of UT-15, United Therapeutics' breakthrough product to treat pulmonaryhypertension (PH)... -- The study showed that UT-15 treatment resulted in an improvement in the gold-standard measurement of efficacy in PH trials: the distance a patient can walk on a treadmill in six minutes. Specifically, between baseline and week 8, mean walking distance increased with UT-15 (+28 m), while it declined with placebo (-6 m). In addition, pulmonary vascular resistance (PVR), a measurement of strain on the heart, decreased an average of 4.9 units (20%) for UT-15-treated patients and increased 0.4 units for placebo-treated patients. -- UT-15 was generally well tolerated. The most common adverse events were injection site pain and redness, which were adequately controlled with treatment. Importantly, this study demonstrated that UT-15 can be administered subcutaneously safely with desirable biological effects, eliminating the need for a central venous catheter that puts patients at risk of life-threatening infections, as required with Flolan, the only currently approved treatment for advanced PH. -- Based on our conversations with several UT-15 investigators, we believe that excitement is building for the product and that the market for UT-15 is considerably larger than that for Flolan, which currently sells nearly $100 million annually. These conversations reinforce our view of the $250-plus million sales potential for UT-15.